Resources


December 24, 2019

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial ...

Continue Reading

December 16, 2019

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming

Presentation Demonstrates Advantages of iBio’s Recently Launched FastGlycaneering Development Service™ -

Continue Reading

December 10, 2019

iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today unveiled the FastGlycaneering Development Service™, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. ...

Continue Reading

December 3, 2019

iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative

iBio to Support the 3D Bioprinting Industry with Enabling Biomaterials NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it is now part of a new public-private Manufacturing USA initiative, the Advanced ...

Continue Reading

September 18, 2019

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen ...

Continue Reading
1 2 3